Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Synact in Media

2021
  • 2022
  • 2020
  • 2019
  • 2018
  • All years
December 10, 2021

SynAct discusses AP1189 with Sedermera

December 10, 2021

MedWatch: Synact Pharma vil intensivere partner-drøftelser

December 7, 2021

SynAct discusses AP1189 Phase 2a results with Direkt

December 3, 2021

BioStock Studio: SynAct Pharma comments on the promising study results in RA

November 30, 2021

SynAct Pharma’s AP1189 meets primary endpoint – Nordic Life Science – the leading Nordic life science news service

November 30, 2021

Scrip: SynAct Surveys Its Options As Rheumatoid Arthritis Asset Succeeds At Phase II

November 11, 2021

BioStock: SynAct Pharma’s CSO and CMO comment on clinical development

July 28, 2021

Nordic Life Science News: SynAct Pharma announces positive additional trial data

June 30, 2021

DagensPS: Lungfunktion vid Covid-19 förbättras med svensk läkemedelskandidat

June 17, 2021

Healthcare Direkt v. 24 l Synact Pharma om kommande fas 2-resultat

February 5, 2021

Finwire – En tydlig utvecklingsplan för AP1189 stärker förhandlingspositionen

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe